China preps for global vaccine push; BioMarin nabs FDA nod for plant expansion;

@FiercePharma: Supreme Court agrees to hear sales-rep overtime suit. Ruling promises to affect the whole industry-WSJ. News | Follow @FiercePharma

> China is gathering its forces for an assault on the global vaccine market, a move that could lower the cost of shots for poor countries--provided safety fears are assuaged. News

> BioMarin Pharmaceutical has won FDA approval for the expansion of its manufacturing facility in Novato, CA, where it makes Aldurazyme and Naglazyme. Item

> Citi's Yaron Werber lowered his price target on Vertex Pharmaceuticals ($VRTX) to $40 from $59, saying the company will face intense competition for its hepatitis C drug Incivek. Article

> Pozen ($POZN) now looks to a profit for 2011 as $75 million migraine-drug rights sale will be booked as revenue. Story

> The Canadian province of Manitoba has added Pfizer's ($PFE) stop-smoking drug Champix (sold as Chantix in the U.S.) to the health system formulary. More

Biotech News

@FierceBiotech: Onyx Pharma shares soar on report of its hunt for options, acquirers. Story | Follow @FierceBiotech

@RyanMFierce: Roche inked a deal with PTC for Spinal Muscular Atrophy program, $30M upfront and $460M in biobucks. | Follow @RyanMFierce

@MaureenFierce: China prepares for big entry into vaccine market. Will be game-changer if China can alleviate safety concerns. Report | Follow @MaureenFierce

> Onyx Pharma shares soar on report of its hunt for options, acquirers. News

> Roche, PTC strike potential $490M deal for genetic disease program. Article

> 22 drugs to watch in 2012. Report

Research News

> Neuron implants fix broken brain circuitry in obese mice. News

> Combo drug offers potent weapon against radiation exposure. Story

> Princeton research could speed pharma discoveries. More

> New target discovered in battle against lymphoma. Piece

Manufacturing News

> McKesson, J&J eye GHX platform for e-pedigree. Item

> Hospira to spend $375M in manufacturing upgrades. Report

> Europe takes precautions with Ben Venue drugs. News

> Ranbaxy, FDA near $400M deal on longstanding violations. Story

> McKesson, J&J eye GHX platform for e-pedigree. Article

And Finally... Vaccinating children more than a year old against chickenpox offers 'tremendous indirect benefits' to infants, researchers said. Report

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.